{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:24:11Z","timestamp":1783650251395,"version":"3.55.0"},"reference-count":38,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K06783"],"award-info":[{"award-number":["JP18K06783"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,1,28]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to assess whether the combined use of proton pump inhibitors (PPIs) with non-steroidal anti-inflammatory drugs (NSAIDs) or antibiotics (penicillins, macrolides, cephalosporins or fluoroquinolones) was associated with an increased risk of acute kidney injury (AKI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A nested case\u2013control study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>A health insurance claims database constructed by the Japan Medical Data Center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients were eligible if they were prescribed a PPI, NSAID and antibiotic at least once between January 2005 and June 2017. The patients who were new PPI users and did not have any history of renal diseases before cohort entry were included (n=219\u2009082). The mean age was 45 and 44% were women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Current use of PPIs, NSAIDs, or antibiotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome measures<\/jats:title>\n                    <jats:p>Acute kidney injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During a mean follow-up of 2.4 (SD, 1.7) years, 317 cases of AKI were identified (incidence rate of 6.1\/10 000 person-years). The current use of PPIs was associated with a higher risk of AKI compared with past PPI use (unadjusted OR, 4.09; 95% CI, 3.09 to 5.44). The unadjusted ORs of AKI for the current use of PPIs with NSAIDs, cephalosporins and fluoroquinolones, compared with the current use of PPIs alone, were 3.92 (95% CI, 2.40 to 6.52), 2.57 (1.43 to 4.62) and 3.08 (1.50 to 6.38), respectively. The effects of concurrent use of PPIs with NSAIDs, cephalosporins or fluoroquinolones remain significant in the adjusted model. The analyses on absolute risk of AKI confirmed the results from the nested case\u2013control study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Concomitant use of NSAIDs with PPIs significantly increased the risk for AKI. Moreover, the results suggested that concomitant use of cephalosporins or fluoroquinolones with PPIs was associated with increased risk of incident AKI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-041543","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T20:05:13Z","timestamp":1613419513000},"page":"e041543","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case\u2013control study"],"prefix":"10.1136","volume":"11","author":[{"given":"Keiko","family":"Ikuta","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-122X","authenticated-orcid":false,"given":"Shunsaku","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Momo","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-6768","authenticated-orcid":false,"given":"Atsushi","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"},{"name":"Graduate School of Faculty of Pharmaceutical Science, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Itohara","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"},{"name":"Department of Pharmacy, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"2025121510013400000_11.2.e041543.1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw470"},{"key":"2025121510013400000_11.2.e041543.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.01.031"},{"key":"2025121510013400000_11.2.e041543.3","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/jcph.805","article-title":"Proton pump inhibitors are not associated with acute kidney injury in critical illness","volume":"56","author":"Lee","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2025121510013400000_11.2.e041543.4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2025121510013400000_11.2.e041543.5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015121377"},{"key":"2025121510013400000_11.2.e041543.6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","article-title":"Association between proton pump inhibitor use and risk of progression of chronic kidney disease","volume":"153","author":"Klatte","year":"2017","journal-title":"Gastroenterology"},{"key":"2025121510013400000_11.2.e041543.7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/phar.2235","article-title":"Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study","volume":"39","author":"Hart","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2025121510013400000_11.2.e041543.8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-150"},{"key":"2025121510013400000_11.2.e041543.9","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20140074"},{"key":"2025121510013400000_11.2.e041543.10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40264-018-0663-1","article-title":"Use of proton pump inhibitors and the risk of acute kidney injury among patients with rheumatoid arthritis: cohort study","volume":"41","author":"Svanstr\u00f6m","year":"2018","journal-title":"Drug Saf"},{"key":"2025121510013400000_11.2.e041543.11","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00990119"},{"key":"2025121510013400000_11.2.e041543.12","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019070676"},{"key":"2025121510013400000_11.2.e041543.13","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3329"},{"key":"2025121510013400000_11.2.e041543.14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40780-015-0016-5","article-title":"Pharmacoepidemiology in Japan: medical databases and research achievements","volume":"1","author":"Tanaka","year":"2015","journal-title":"J Pharm Health Care Sci"},{"key":"2025121510013400000_11.2.e041543.15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jamaneurol.2018.0278","article-title":"Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population","volume":"75","author":"Mushiroda","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025121510013400000_11.2.e041543.16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pupt.2018.04.003","article-title":"Assessment of statin-induced interstitial pneumonia in patients treated for hyperlipidemia using a health insurance claims database in Japan","volume":"50","author":"Momo","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"2025121510013400000_11.2.e041543.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001821"},{"key":"2025121510013400000_11.2.e041543.18","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1798"},{"key":"2025121510013400000_11.2.e041543.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.03.008"},{"key":"2025121510013400000_11.2.e041543.20","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfy187","article-title":"Risk of acute kidney injury following community prescription of antibiotics: self-controlled case series","volume":"34","author":"Rennie","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2025121510013400000_11.2.e041543.21","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.04.027"},{"key":"2025121510013400000_11.2.e041543.22","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1660"},{"key":"2025121510013400000_11.2.e041543.23","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.140950"},{"key":"2025121510013400000_11.2.e041543.24","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.121730"},{"key":"2025121510013400000_11.2.e041543.25","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.74"},{"key":"2025121510013400000_11.2.e041543.26","doi-asserted-by":"publisher","DOI":"10.1186\/cc13054"},{"key":"2025121510013400000_11.2.e041543.27","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.08.024"},{"key":"2025121510013400000_11.2.e041543.28","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/SLA.0000000000001582","article-title":"Acute and chronic kidney disease and cardiovascular mortality after major surgery","volume":"264","author":"Ozrazgat-Baslanti","year":"2016","journal-title":"Ann Surg"},{"key":"2025121510013400000_11.2.e041543.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.03.012"},{"key":"2025121510013400000_11.2.e041543.30","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"2025121510013400000_11.2.e041543.31","doi-asserted-by":"publisher","DOI":"10.2307\/2291379"},{"key":"2025121510013400000_11.2.e041543.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e8525"},{"key":"2025121510013400000_11.2.e041543.33","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.101"},{"key":"2025121510013400000_11.2.e041543.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03407.x"},{"key":"2025121510013400000_11.2.e041543.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61454-2"},{"key":"2025121510013400000_11.2.e041543.36","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318168e375"},{"key":"2025121510013400000_11.2.e041543.37","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006010073"},{"key":"2025121510013400000_11.2.e041543.38","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010010128"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-041543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:01:43Z","timestamp":1765821703000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-041543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,15]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bmjopen-2020-041543"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-041543","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}